Oncologie Team

Our global team has deep scientific knowledge, extensive pharmaceutical experience as well as proven clinical and business acumen.

Grand Opening New Office in Waltham, MA

Grand Opening New Office in Waltham, MA

Garden in Souzhou

Garden in Souzhou

Oncologie Leadership


IMG_0078 (2).jpg

Laura Benjamin, PhD


Founder and CEO

PhD in Molecular Biology from the University of Pennsylvania

BA in Biology from Barnard College, Columbia University


Laura brings scientific vision and leadership experience from her years as faculty at Harvard Medical School and Vice President at ImClone Systems and Eli Lilly. She has focused her scientific career on cancer biology and clinical biomarker strategies.


David Malek, MBA


Chief Business Officer

MBA from Tuck School of Business, Dartmouth College



David brings experience in business development as well as executive managerial experience in public companies, Sanofi and BiolineRx.

Jess Head Shot.jpg

Jessicca Rege, PhD

Chief Development Officer

PhD in Pharmaceutical Sciences Virginia Commonwealth University

MS in Physiology from Virginia Commonwealth University

BA in Biology from Carson Newman College


Jessicca is an experienced oncology leader with over ten years of experience in the pharmaceutical field. She most recently served as Global Chief of Staff for the Cancer Enterprise in Daiichi-Sankyo where she took a central role in supporting the Global Head of Oncology R&D in both strategic planning and implementation of their global portfolio. Prior to this, she held various leadership roles in both large and small pharmaceutical companies in both clinical development and medical affairs supporting the development and approval of oncology products, such as Cyramza® , Halaven®, Lenvima®, and Sprycel®.


Hagop Youssoufian, MD

Acting Chief Medical Officer

MD from University of Massachusetts Medical School

Fellowships in Genetics at Johns Hopkins and

Hematology-Oncology at Massachusetts General Hospital



Hagop is an experienced oncology drug developer with tenures in several pharmaceutical and biotech companies, including as Chief Medical Officer at ImClone-Lilly and as President of R&D at Ziopharm. He was involved in the development and approval of multiple oncology biologic products, such as Erbitux®, Cyramza®, and Taxotere®.